Nucleotide-binding domain and leucine-rich repeat protein 3 inflammasome inhibitor for treating inflammatory intestinal diseases

Abstract

The present invention provides a method of treating a disease mediated by NLRP3 inflammasomes in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of compound 2′,4′-dihydroxychalcone. The compound 2′,4′-dihydroxychalcone inhibits the activation of NLRP3 inflammasomes and reduces the secretion level of pro-inflammatory factors by inhibiting the activation of Caspase-1 and the expression of NLRP3.

Dependencies are inferred from the claim text.